Sentences with phrase «cell lymphoma patient»
B cell suppression in newborn following treatment of pregnant diffuse large B - cell lymphoma patient with rituximab containing regimen.
http://www.immunohorizons.org/
High serum vascular endothelial growth factor level is an adverse prognostic factor for high - risk diffuse large B - cell lymphoma patients treated with dose - dense chemoimmunotherapy.
The outcome of peripheral T - cell lymphoma patients failing first line therapy: a report from the prospective, international T - Cell project.
Not exact matches
In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatment.
KTE - C19 spurred either a complete or partial response in 13 out of 19 patients with large B - cell lymphomas.
Announced a clinical trial collaboration with Pfizer, Inc. (Pfizer) to evaluate the safety and efficacy of the investigational combination of Yescarta and Pfizer's utomilumab, a fully humanized 4 - 1BB agonist monoclonal antibody, in patients with refractory large B - cell lymphoma.
The drug, which was first approved last August for patients under 25 with B - cell precursor acute lymphoblastic leukemia, is now OK» ed to treat large B - cell lymphoma.
One of Juno's rivals, Kite Pharma, yesterday said it had completed its enrollment of 72 patients with diffuse large B - cell lymphoma in the Phase II portion of the ZUMA - 1 trial, designed to assess KTE - C19.
Juno is developing its immunotherapy product candidate, JCAR017, which is in a Phase I trial, studying patients with B - cell Non-Hodgkin Lymphoma [NHL].
Dr. Newman added that rival CAR T cell therapy developer Kite Pharma was still likelier to generate more revenue than Juno with KTE - C19, which last week completed patient enrollment in the Phase II portion of the ZUMA - 1 trial in patients with diffuse large B - cell lymphoma.
Novartis, for example, spent $ 43 million on a manufacturing facility in Morris Plains, New Jersey, and last week it released results from a lymphoma trial in which cells were frozen and flown to and from patients in 10 countries.
However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells.
The Penn team, in collaboration with Alain Rook, MD, director of the Cutaneous T - cell Lymphoma Program and a professor of Dermatology, aims to develop a molecular taxonomy for mutations in SS patients.
With that idea in mind, Karmali is leading an innovative Phase II clinical trial evaluating the effectiveness of combining the diabetes medication metformin with standard chemotherapy to treat patients with diffuse large B - cell lymphoma.
Breast implant - associated anaplastic large cell lymphoma — or BIA - ALCL — is a rare peripheral T - cell lymphoma that may develop in patients with breast implants.
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B - cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.
Some patients with non-small cell lung cancer (NSCLC) have changes in the anaplastic lymphoma kinase (ALK) gene, which can drive the development of their cancer.
«Patients with non-small cell lung cancer (NSCLC) should receive front line therapy with the anaplastic lymphoma kinase (ALK) inhibitor crizotinib,» said lead author Professor Giorgio Scagliotti, head of the Department of Oncology, University of Turin, Italy.
Experience with lymphoma patients, who receive a transplant of their own blood or bone cells after radiation to wipe out their cancer, has shown «there's no doubt it helps,» says bone marrow transplant expert Nelson Chao of Duke University in Durham, North Carolina.
To block this signal, recent clinical studies have focused on inhibiting the activation of the B - cell receptor as a treatment for non-Hodgkin lymphoma patients, but with variable success.
Professor Gandhi said results from a landmark study regarding the tool would help clinicians identify the best course of action for patients with Diffuse Large B - Cell Lymphoma (DLBCL).
Rituximab, a monoclonal antibody that attacks cancer cells in patients with a certain subtype of B - cell lymphoma, was approved by the Food and Drug Administration in 1997.
The approach, which is described in a paper to be published September 7 in The Journal of Experimental Medicine, could allow those in need of such transplants, including leukemia and lymphoma patients, to be treated with fewer donor stem cells while limiting potential adverse side effects.
In recent clinical trials, CAR T cell therapy has dramatically improved the outcomes of blood cancer patients with advanced, otherwise untreatable forms of leukemia and lymphoma.
Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL)-- a rare type of non-Hodgkin lymphoma that affects the skin.
«Topical gel proves safe, effective treatment for patients with skin t cell lymphoma.»
Since 2011, though, experimental CAR T cell treatments for B cell leukemias and lymphomas — cancers in which patients» healthy B cells turn cancerous — have been successful in some patients for whom all standard therapies had failed.
Beilhack and colleagues found that a slightly modified version of STAR2 has a similar effect on human T reg cells, suggesting that the approach could also prevent GvHD in leukemia and lymphoma patients after bone marrow or hematopoietic stem cell transplants.
A unique approach to targeting the abnormal T - cells that cause T - cell lymphomas could offer hope to patients with the aggressive and difficult - to - treat family of cancers, finds a study involving researchers from Cardiff University.
The therapy is approved by the U.S. Food and Drug Administration for relapsed or treatment - resistant Hodgkin lymphoma, and it is commonly prescribed to patients whose disease has progressed after autologous stem cell transplant, a procedure that replenishes the bone marrow with the patient's own healthy stem cells after therapy.
High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B - Cell Lymphoma (DLBCL) Patients Treated with Dose - Dense Chemoimmunotherapy and Systemic CNS Prophylaxis.
«Autologous stem cell transplant should be standard care for HIV - associated lymphoma: Multicenter, Phase II trial suggests autologous transplant should be standard of care for HIV patients with relapsed / treatment - resistant lymphoma.»
Based on our data, autologous stem cell transplant should be considered the standard of care for patients with HIV - related lymphomas for the same indications and under the same circumstances that we would use it in patients without HIV infection.»
Dose - densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high - risk diffuse large B - cell / follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Groulymphoma patients: results of a phase II Nordic Lymphoma GrouLymphoma Group study.
Exon - Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B - Cell / Follicular Grade 3 Lymphoma Patients Treated with Dose - Dense Chemoimmuno - therapy and CNS Prophylaxis.
The FDA granted accelerated approval to nivolumab (Opdivo), an anti-PD-1 checkpoint inhibitor, for patients with classical Hodgkin lymphoma (cHL) whose disease has relapsed or progressed after stem cell transplantation and the targeted antibody brentuximab vedotin (Adcetris).
The FDA granted approval to Yescarta ™ (axicabtagene ciloleucel, Kite / Gilead) for the treatment of adult patients with several types of non-Hogdkin large B cell lymphoma that is refractory or has relapsed after at least two previous systemic treatments.
The FDA granted approval to rituximab and hyaluronidase (Rituxan Hycela) for patients with follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).
CHOP Chemotherapy Plus Rituximab Compared With CHOP Alone In Elderly Patients With Diffuse Large B - Cell Lymphoma
Ronald Levy reports the first successful treatment of a patient with a monoclonal antibody against the idiotype of a B cell lymphoma.
But efforts to develop adoptive T cell therapies for solid tumors have hit upon a number of challenges; the only gene therapies to show significant benefit for patients have been in liquid tumors — forms of leukemia and lymphoma.
Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
Hematopoetic stem cell mobilization in patients with Leukemia, Lymphoma and Multiple Myeloma
Heidi Simmons decided to focus on cell therapy for treatment of blood cancers like leukemia, lymphoma and myeloma, where healthy cells are infused into patients to replenish those damaged by cancer.
Hematopoietic stem cell mobilization in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease
Safety, Pharmacokinetics and Stem Cell Mobilization of TG - 0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients.
Scope: 22 institutions Treatment: CD19 - targeting CAR T - cell therapy Results: 42 % of patients with aggressive large B - cell lymphoma remained in remission after 15 months
Brentuximab vedotin was previously approved by the FDA to treat cHL after relapse, cHL after stem cell transplant when a patient is at a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after failure of other treatment, and primary cutaneous ALCL after failure of other treatment.
«With the FDA's recent approval of this therapy, we believe this is a major advance in the treatment of patients with relapsed or refractory large B - cell lymphoma, and is likely to save or prolong lives of many patients,» says Neelapu.
Administration of chemotherapy to patients hospitalized with diffuse large B cell lymphoma (DLBCL) was associated with lower odds of death during hospitalization, according to the results of a study published in Cancer Epidemiology.